

Patient Perspective: ICE-HBV Cure Strategy

June 18, 2019

Joan M. Block, RN, BSN

Co-Founder and Senior Advisor, Hepatitis B Foundation

Joan.Block@hepb.org

Why ICE-HBV is Important to the Community

- 1st International Coalition to Eliminate (ICE) Hepatitis B Virus (HBV), which has made an HBV Cure a global research priority.
 - ➤ ICE-HBV evolved from the *International HBV Meeting*, an annual scientific meeting coordinated by Hepatitis B Foundation.
- The ICE-HBV Global Scientific Cure Strategy provides a research plan to achieve WHO's goal to end chronic viral hepatitis by 2030.
 - > It includes community stakeholders even at this early stage.

An HBV Cure Is Urgently Needed

- Almost 1 million people living with chronic HBV (CHB) continue to die every year despite 8 approved drugs!
- Current treatments only <u>control</u> the virus there is NO cure.
- With the current treatment guidelines, only 50% of CHB patients qualify for the approved drugs.
- And the risk of death due to liver disease only drops by 50-70% for those treated with the current oral HBV drugs.

Clearly, we need an HBV Cure to finally eliminate the deadly hep B virus.

HCV Is Curable – Why Isn't HBV?

- In 2013, the first approved HCV cure was approved.
 - Today, HCV patients can be cured in as little as 8 weeks.
- Scientists never thought HCV could be cured.
 - Today, scientists are now taking a second look at HBV.
- Key Point: If NIH and pharma invested as much in HBV as they did for HCV, we could also expect a similar miracle.

Hence, today the expectation for an HBV cure is even greater!

What Would An HBV Cure Cost?

- The potential for eliminating HBV has been established by WHO and the U.S. NASEM reports.
- NIH currently funds HBV at \$49 Million per year, but funding has declined 16% since 2012.
- We need the NIH because it has the infrastructure and scientific capacity needed to accelerate the pace of research for HBV.
- In 2018, the Hepatitis B Foundation published its "Roadmap for a Cure" that includes a Professional Judgement Budget for the NIH.

Dollars Equal Concern

- The HBF *Professional Judgement Budget* projects almost a \$39 Million average annual increase for the NIH (over the current \$49M per year).
 - Only an additional \$234 Million over 6 years through 2023.
- NIH annually spends \$3.2 Billion on HIV/AIDS.
- Additional NIH funds for HBV would support (i) Basic Science Studies and (ii) Translational/Clinical Research.
- Studies would be based on priorities and milestones identified in the HBF Research Roadmap for a Cure and the ICE-HBV Cure Strategy.

A Cure Could Largely Eliminate HBV By 2030

An HBV Cure will save almost 170,000 lives in the U.S. by 2030 Current level of projected deaths is 188,000 (see column A below)

Table 2: Projected Health Outcomes for 2,000,000 Americans with Chronic HBV by 2030 using Three Levels of Diagnosis and Treatment: Current Level, Substantially Improved, HBV Cure.*

		A) Current Level	B) Substantially Improved	C) HBV Cure
	Death	188,000	93,210	18,800
	Liver Cancer	120,000	78,204	12,000
	Cirrhosis	206,200	114,088	20,620


^{*}Adapted from NASEM, Toy, 2017

Source: Hepatitis B Foundation's Research Roadmap for a Cure 2018

Investing In An HBV Cure

The human toll and the economic burden is substantial and the data provides compelling evidence for investing in an HBV cure.

Table 3: Sample Costs Per Patient for Treating Chronic HBV







Today's Key Points:

- 1. Finally, we now have the scientific and technological capability to find a cure;
- 2. We have the public health mandates from NASEM and WHO;
- 3. We have the research roadmaps from HBF and ICE-HBV.

NOW WE NEED

VOCAL ADVOCACY FROM THE HBV COMMUNITY

TO CALL FOR ACTION!

Make Hepatitis B History!!

An HBV Cure would truly free those living with chronic hepatitis B from the burden of disease and the related stigma and discrimination.

Ultimately, together we can make hepatitis B history!

Thank you . . .